188576-49-0

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 7-HYDROXY-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE is used as a reagent for the preparation of biologically active small molecules. Its role in the synthesis of these molecules is crucial, as it can contribute to the development of new drugs and therapies for various medical conditions.
Used in Chemical Industry:
In the chemical industry, TERT-BUTYL 7-HYDROXY-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE is utilized as a reagent for the synthesis of various chemical compounds. Its unique properties and reactivity make it a valuable component in the development of new materials and products with potential applications in various fields.

InChI:InChI=1/C14H19NO3/c1-14(2,3)18-13(17)15-7-6-10-4-5-12(16)8-11(10)9-15/h4-5,8,16H,6-7,9H2,1-3H3

Upstream product

• 30798-64-2 7-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 110192-19-3 7-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide 
• 39989-39-4 7-methoxyisoquinoline 
• 7651-83-4 isoquinolin-7-ol 
• 1700-37-4 3-Benzyloxybenzaldehyde 
• 123-91-1 1,4-dioxane 
• 94086-06-3 C₁₆H₁₇NO 
• 937048-76-5 7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 258515-65-0 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester 
• 17680-55-6 7-bromo-1,2,3,4-tetrahydroisoquinoline 
• 188576-56-9 1,2,3,4-tetrahydro-isoquinolin-7-ol acetate 
• 591-31-1 3-methoxy-benzaldehyde 
• 43207-78-9 7-methoxy-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 247132-98-5 benzyl 4-(2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)piperidin-1-carboxylate 
• 215453-91-1 tert-butyl 7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1315319-88-0 C₂₇H₂₃ClN₂S 
• 1203600-36-5 tert-butyl 7-[({4-[(benzyloxy)methyl]-1-(pyridin-4-yl)piperidin-4-yl}carbonyl)oxy]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1203600-33-2 tert-butyl 7-{[4-(pyrrolidin-1-ylcarbonyl)benzoyl]oxy}-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1203600-46-7 tert-butyl 7-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}benzoyl)oxy]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1203600-48-9 benzyl 4-{4-[({2-[amino(imino)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}oxy)carbonyl]phenoxy}piperidine-1-carboxylate trifluoroacetate 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 247133-24-0 8-hydroxy-2,3,4,5-tetrahydro-1H-benz[c]azepine-2-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION

Disclosed are a class of new monocyclic β-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated

DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.

ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS

The invention discloses compounds of the formula wherein A, B, X, Y and Z are defined. The compounds of the invention show activity against a range of bacteria, and are useful in the treatment or prophylaxis of a bacterial infection in an animal.

Of tetracyclic Anaplastic lymphoma kinase inhibitors (by machine translation)

The invention belongs to the field of medical technology, in particular to general formula (I) as shown in of tetracyclic Anaplastic lymphoma kinase inhibitor, its pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 1, R 2, R 3, R 4, R 5 and A link like defined in the specification. The invention also relates to methods of preparing such compounds, pharmaceutical preparations comprising these compounds and pharmaceutical composition, the compound and, its pharmaceutically acceptable salts or stereoisomers thereof, in the preparation of the treatment and/or prevention of Anaplastic lymphoma kinase-mediated cancer diseases related to the application of the medicament. (by machine translation)

Identification of non-amidine inhibitors of acid-sensing ion channel-3 (ASIC3)

A series of benzothiophene methyl amines were examined in an effort to identify non-amidine chemotypes with reduced polypharmacology from existing leads with the goal of finding potent ASIC3 channel blockers to advance the therapeutic evaluation of ASIC3

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

AMIDINE DERIVATIVE

Provision of a novel amidine derivative or a pharmaceutically acceptable salt thereof having an activated blood coagulation factor X-inhibitory activity. A compound represented by the formula (I) wherein each symbol is as defined above, or a pharmaceutically acceptable salt thereof.

Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation and structure-activity relationships. Part 2

The design, synthesis and evaluation of novel thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as cyclin-dependent kinase 4 (CDK4) inhibitor are described. Focusing on the optimization of the heteroaryl moiety at the hydrazone with substituted phenyl group

Highly potent and selective zwitterionic agonists of the δ-opioid receptor. Part 1

A series of zwitterionic δ-opioid agonists, with targeted physicochemistry, as a strategy to limit potential for CNS exposure, were prepared. These agents were found to possess exquisite potency and selectivity over mu and κ-opiate activity. Furthermore,